Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013
Timothy J Price, Eva Segelov, Matthew Burge, Daniel G Haller, Niall C Tebbutt, Christos S Karapetis, Cornelis JA Punt, Nick Pavlakis, Dirk Arnold, Peter Gibbs, Jeremy D Shapiro
Expert Review of Anticancer Therapy | TAYLOR & FRANCIS LTD | Published : 2014
The Australian authors have received honoraria and travel support to attend national and international meetings for colorectal cancer from Merck Serono, Amgen, Roche and Sanofi Aventis. Disclosures for the international faculty are as follows: Punt CJA, advisor for Roche, Merck, Amgen, Bayer, Sanofi, Nordic Pharma; Dirk Arnold Research Funding Roche; Daniel Haller Consultant/honoraria, Sanofi-Aventis, Amgen, Genentech; Research funding Roche. The group meeting that enabled the material for this review to be assembled was supported by an unrestricted educational grant from Roche provided to the 'Adelaide Colorectal Tumour Group', which facilitated the meeting. Roche did not participate in data compilation or in the writing or viewing the submitted review. The corresponding author has had full access to all the data, warrants that all information has been reviewed and accepted by all participants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.